IE
CERO

Israel Englander’s CERo Therapeutics CERO Stock Holding History

Israel Englander’s Portfolio CERO Stock Details CERO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-32
Closed -$3.78K – 6492
2024
Q4 		$3.78K Buy
+32
New +$7.46K ﹤0.01% 5827
2023
Q1 		– Sell
-109
Closed -$2.23M – 6953
2022
Q4 		$2.23M Sell
109
-2
-2% -$40.8K ﹤0.01% 3481
2022
Q3 		$2.23M Hold
111
– – ﹤0.01% 3640
2022
Q2 		$2.22M Buy
111
+2
+2% +$40.1K ﹤0.01% 3604
2022
Q1 		$2.18M Buy
+109
New +$2.17M ﹤0.01% 3798

Other funds holding CERO

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
APP
Avantax Planning Partners Dubuque, Iowa $4.02B AUM 20% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Israel Englander's CERO Position: Q1 2025 in Review

Israel Englander sold out of CERo Therapeutics (CERO) in Q1 2025, closing a stake of 32 shares — an estimated $3.78K sold.

Israel Englander first reported a position in CERO in Q1 2022 and held it in 5 quarters. The position peaked at $2.23M in Q4 2022. 13 funds tracked by Wall St. Rank hold CERO as of Q1 2025.

  • Israel Englander reported no remaining CERo Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Israel Englander sold 32 CERo Therapeutics shares in Q1 2025, an estimated $3.78K.
  • Israel Englander first reported a position in CERo Therapeutics in Q1 2022 and held it in 5 quarters.
  • Israel Englander's CERo Therapeutics position peaked at $2.23M in Q4 2022.
  • 13 funds tracked by Wall St. Rank held CERo Therapeutics as of Q1 2025.

Based on Millennium Management's 13F filing for Q1 2025, filed 15 May 2025.